CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)
To estimate comparative effectiveness, in terms of objective response rate (ORR), progression free and overall survival (PFS, OS) using unanchored MAIC of single-arm LIBRETTO-001 (selpercatinib) and EXAM trials (cabozantinib vs placebo) in advanced/metastatic RET mutation-positive MTC.
Source: Value in Health - Category: International Medicine & Public Health Authors: M.H. Jen, U. Kiiskinen, M. Khanal, Y. Han, L. Hess, W. Tian, A. Vickers Source Type: research
More News: Cancer | Cancer & Oncology | International Medicine & Public Health | Thyroid | Thyroid Cancer